• Applied Workflows with EZ Cap™ Cy5 EGFP mRNA (5-moUTP)

  2026-05-09

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) empowers real-time dual fluorescence tracking and robust translation readouts, streamlining gene delivery optimization. Its immune-evasive, Cap 1–capped structure and Cy5 labeling enable precise quantification of both mRNA uptake and protein expression—addressing key bottlenecks in advanced gene regulation and delivery system development.

• Protease and Phosphatase Inhibitor Cocktail: Workflow & Trou

  2026-05-08

  Unlock uncompromised protein integrity and phosphorylation preservation with the Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O). This guide translates bench research into actionable protocols, advanced use-cases, and troubleshooting insights—empowering robust results for cell signaling and proteomics.

• Dovitinib (TKI-258): Workflow Advances in RTK-Driven Cancer

  2026-05-07

  Dovitinib (TKI-258) is a multitargeted RTK inhibitor that enables reproducible, high-fidelity apoptosis induction and pathway dissection in challenging cancer models. This article details experimental workflows, protocol optimizations, and troubleshooting strategies for maximizing Dovitinib’s translational impact in oncology research.

• Thiazovivin for Reliable ROCK Inhibition in Stem Cell Workfl

  2026-05-07

  Thiazovivin is a highly pure ROCK inhibitor optimized for enhancing induced pluripotent stem cell (iPSC) generation and human embryonic stem cell (hESC) survival during critical cell handling steps. It is best suited for in vitro research applications requiring consistent cell survival and efficient reprogramming, but should not be used for diagnostic or clinical purposes.

• Praeruptorin A: Next-Gen Ferroptosis Inhibitor for Cardiotox

  2026-05-06

  Explore the advanced mechanisms and translational impact of Praeruptorin A, an angular pyranocoumarin compound, as a ferroptosis inhibitor in cardiomyopathy research. This article uniquely focuses on assay design, clinical implications, and protocol optimizations for researchers.

• Proteinase K: Broad-Spectrum Serine Protease for DNA Purity

  2026-05-06

  Leverage Proteinase K's robust proteolytic power for uncompromised DNA isolation—even in the presence of enzymatic contaminants or challenging sample types. Discover precision protocol enhancements, cross-validated troubleshooting, and evidence-backed advantages that set APExBIO’s recombinant Proteinase K (SKU K1037) apart in molecular workflows.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-05-05

  Anlotinib hydrochloride redefines anti-angiogenic research with its nanomolar potency and superior selectivity as a multi-target tyrosine kinase inhibitor. This guide translates high-impact bench evidence into actionable endothelial migration and tube formation assays, with optimization and troubleshooting tips to empower cancer and vascular biology workflows.

• Capsaicin (E)-Capsaicin: Mechanistic Insights and Experiment

  2026-05-05

  Explore the multifaceted roles of Capsaicin in TRPV1 ion channel activation, pain and inflammation signaling, and epigenetic modulation. This in-depth review uniquely deciphers mechanistic advances and strategic assay design, setting it apart from protocol-focused resources.

• 5-Methyl-CTP: Precision Control of mRNA Immunogenicity and S

  2026-05-04

  Explore how 5-Methyl-CTP empowers researchers to precisely tune mRNA immunogenicity and stability, unlocking next-generation applications in vaccine engineering and therapeutic development. Delve into advanced assay insights and practical protocol strategies using this 5-methyl modified cytidine triphosphate.

• Vorinostat (SAHA): Deep Mechanistic Insights for Advanced Ep

  2026-05-04

  Discover how Vorinostat (suberoylanilide hydroxamic acid) uniquely enables advanced epigenetic modulation and apoptosis studies in oncology. This article unveils new mechanistic insights and practical strategies for cancer biology research beyond conventional HDAC inhibition.

• CCG-1423: Precision RhoA Inhibitor Workflows for Cancer & Vi

  2026-05-03

  CCG-1423, a potent small-molecule RhoA inhibitor from APExBIO, empowers researchers to dissect RhoA/ROCK signaling with unmatched specificity. This article delivers actionable protocol enhancements, troubleshooting strategies, and translational insights for both cancer and viral pathogenesis models.

• Nebivolol hydrochloride: Reliable β1-Adrenoceptor Antagonist

  2026-05-02

  This article delivers an evidence-based, scenario-driven guide for using Nebivolol hydrochloride (SKU B1341) in cell viability and β1-adrenergic receptor signaling research. Emphasizing experimental reliability and mechanistic specificity, it addresses key workflow questions and comparative product selection, highlighting the unique advantages offered by APExBIO's high-purity Nebivolol hydrochloride.

• Repurposing Natural Compounds Against SARS-CoV-2: Docking In

  2026-05-02

  This study identifies several natural compounds and vitamins with potential to inhibit SARS-CoV-2 by targeting its main protease (3CLpro) and the spike protein receptor-binding domain, using molecular docking and dynamics analyses. The findings highlight new directions for antiviral therapeutics research, emphasizing the value of in silico repurposing to accelerate COVID-19 drug discovery.

• Lactate-Driven HMGB1 Lactylation and Release in Sepsis Macro

  2026-05-01

  This study reveals that extracellular lactate actively induces both lactylation and acetylation of HMGB1 in macrophages, promoting its exosomal release during polymicrobial sepsis. The mechanistic insights presented offer new therapeutic angles for modulating inflammation and highlight critical considerations for accurate study of post-translational modifications.

• Simvastatin Induces Autophagy in Prostate Cancer Cells: Mech

  2026-04-30

  This study demonstrates that Simvastatin induces autophagy and inhibits proliferation in multiple prostate cancer cell lines. The findings clarify the mechanistic basis for Simvastatin's anti-cancer potential and highlight combinatorial strategies for maximizing tumor suppression in resistant prostate cancer models.

454 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page